HER2+ Breast Cancer: Special Challenges and Expert Insight

Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.

An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.

Key opinion leaders explore the appropriateness of prophylactic therapy for brain metastases and share their thoughts on best practices.

Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.

A panel of experts weighs in the challenges of optimally sequencing therapy for patients with HER2+ breast cancer.

Experts in breast cancer respond to polling questions surrounding the recognition of pneumonitis and interstitial lung disease.

Experts discuss the careful monitoring of potential interstitial lung disease symptoms, how they proceed if symptoms progress, and how they handle this in patients who are asymptomatic.

Expert panelists react to polling questions and give their input on the management both symptomatic and asymptomatic interstitial lung disease in HER2+ breast cancer, also touching on this impact in the era of COVID-19.

Key opinion leaders discuss recent advancements and future directions in the HER2+ breast cancer space.

This article discusses recent developments in HER2-targeted therapies and new challenges for clinicians treating patients with HER2-positive breast cancer, and includes expert insights from Adam M. Brufsky, MD, PhD, of the University of Pittsburgh Medical Center in Pittsburgh, PA, V.K. Gadi, MD, PhD, of the University of Illinois in Chicago, IL, and Sara A. Hurvitz, MD, of the David Geffen School of Medicine at the University of California Los Angeles, in Los Angeles, CA, and Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center in New York, NY.